Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts

Joshua A. Waters, Jesus Matos, Michele Yip-Schneider, Juan R. Aguilar-Saavedra, Colin D. Crean, Joal D. Beane, Ryan P. Dumas, Attaya Suvannasankha, C. Max Schmidt

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background Pancreatic ductal adenocarcinoma (PDAC) is an almost uniformly fatal malignancy characterized by resistance to chemotherapy. Currently, gemcitabine is the agent used most commonly but demonstrates only a partial response. The transcription factor nuclear factor-kappaB (NF-κB), known to be involved in the inflammatory response, is constitutively activated in PDAC and further activated by gemcitabine. Our aim was to examine the effects of targeted NF-κB suppression on gemcitabine resistance using an in vivo tumor growth model. Methods To suppress the NF-κB pathway, the mutant IκBα super-repressor protein was stably expressed in PaCa-2 human PDAC cells. Athymic mice were injected subcutaneously with IκBα-super-repressor (SR) or vector-expressing PaCa-2 cells and randomized to receive phosphate-buffered saline (PBS) or 100 mg/kg gemcitabine(gem) for 4 weeks. Results The mean increase in tumor volume was 47 mm3 (89%) and 196 mm3 (326%) in gem/SR and gem/vector groups, respectively (P =.03). The PBS-treated groups demonstrated greater tumor growth, ∼340 mm3 (850%) increase, in both PBS/vector and PBS/SR groups. Intratumoral NF-κB activity was decreased in gem/SR compared with the gem/vector group (P =.04). Decreased Ki-67 positivity was noted in gem/SR (49%) versus gem/vector tumors (73%) (P =.04), with no difference in apoptosis (apoptag, P =.3) or angiogenesis (CD31+, P =.9). Conclusion Stable IκBα-SR expression in vivo potentiated the antitumor effects of gemcitabine, resulting in decreased tumor growth in association with decreased cell proliferation. Molecular suppression of the NF-κB pathway decreases successfully gemcitabine resistance in a relatively chemoresistant PDAC line. Thus, NF-κB-targeted agents may complement gemcitabine-based therapies and decrease chemoresistance in patients with PDAC.

Original languageEnglish (US)
Pages (from-to)881-889
Number of pages9
JournalSurgery (United States)
Volume158
Issue number4
DOIs
StatePublished - Oct 1 2015
Externally publishedYes

Fingerprint

gemcitabine
Tumor Cell Line
Heterografts
Adenocarcinoma
Phosphates
Neoplasms
Growth
Repressor Proteins

ASJC Scopus subject areas

  • Surgery

Cite this

Waters, J. A., Matos, J., Yip-Schneider, M., Aguilar-Saavedra, J. R., Crean, C. D., Beane, J. D., ... Schmidt, C. M. (2015). Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. Surgery (United States), 158(4), 881-889. https://doi.org/10.1016/j.surg.2015.04.043

Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. / Waters, Joshua A.; Matos, Jesus; Yip-Schneider, Michele; Aguilar-Saavedra, Juan R.; Crean, Colin D.; Beane, Joal D.; Dumas, Ryan P.; Suvannasankha, Attaya; Schmidt, C. Max.

In: Surgery (United States), Vol. 158, No. 4, 01.10.2015, p. 881-889.

Research output: Contribution to journalArticle

Waters, JA, Matos, J, Yip-Schneider, M, Aguilar-Saavedra, JR, Crean, CD, Beane, JD, Dumas, RP, Suvannasankha, A & Schmidt, CM 2015, 'Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts', Surgery (United States), vol. 158, no. 4, pp. 881-889. https://doi.org/10.1016/j.surg.2015.04.043
Waters, Joshua A. ; Matos, Jesus ; Yip-Schneider, Michele ; Aguilar-Saavedra, Juan R. ; Crean, Colin D. ; Beane, Joal D. ; Dumas, Ryan P. ; Suvannasankha, Attaya ; Schmidt, C. Max. / Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. In: Surgery (United States). 2015 ; Vol. 158, No. 4. pp. 881-889.
@article{a4df02d15ce54cf08d152047b3bc25a3,
title = "Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts",
abstract = "Background Pancreatic ductal adenocarcinoma (PDAC) is an almost uniformly fatal malignancy characterized by resistance to chemotherapy. Currently, gemcitabine is the agent used most commonly but demonstrates only a partial response. The transcription factor nuclear factor-kappaB (NF-κB), known to be involved in the inflammatory response, is constitutively activated in PDAC and further activated by gemcitabine. Our aim was to examine the effects of targeted NF-κB suppression on gemcitabine resistance using an in vivo tumor growth model. Methods To suppress the NF-κB pathway, the mutant IκBα super-repressor protein was stably expressed in PaCa-2 human PDAC cells. Athymic mice were injected subcutaneously with IκBα-super-repressor (SR) or vector-expressing PaCa-2 cells and randomized to receive phosphate-buffered saline (PBS) or 100 mg/kg gemcitabine(gem) for 4 weeks. Results The mean increase in tumor volume was 47 mm3 (89{\%}) and 196 mm3 (326{\%}) in gem/SR and gem/vector groups, respectively (P =.03). The PBS-treated groups demonstrated greater tumor growth, ∼340 mm3 (850{\%}) increase, in both PBS/vector and PBS/SR groups. Intratumoral NF-κB activity was decreased in gem/SR compared with the gem/vector group (P =.04). Decreased Ki-67 positivity was noted in gem/SR (49{\%}) versus gem/vector tumors (73{\%}) (P =.04), with no difference in apoptosis (apoptag, P =.3) or angiogenesis (CD31+, P =.9). Conclusion Stable IκBα-SR expression in vivo potentiated the antitumor effects of gemcitabine, resulting in decreased tumor growth in association with decreased cell proliferation. Molecular suppression of the NF-κB pathway decreases successfully gemcitabine resistance in a relatively chemoresistant PDAC line. Thus, NF-κB-targeted agents may complement gemcitabine-based therapies and decrease chemoresistance in patients with PDAC.",
author = "Waters, {Joshua A.} and Jesus Matos and Michele Yip-Schneider and Aguilar-Saavedra, {Juan R.} and Crean, {Colin D.} and Beane, {Joal D.} and Dumas, {Ryan P.} and Attaya Suvannasankha and Schmidt, {C. Max}",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.surg.2015.04.043",
language = "English (US)",
volume = "158",
pages = "881--889",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts

AU - Waters, Joshua A.

AU - Matos, Jesus

AU - Yip-Schneider, Michele

AU - Aguilar-Saavedra, Juan R.

AU - Crean, Colin D.

AU - Beane, Joal D.

AU - Dumas, Ryan P.

AU - Suvannasankha, Attaya

AU - Schmidt, C. Max

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background Pancreatic ductal adenocarcinoma (PDAC) is an almost uniformly fatal malignancy characterized by resistance to chemotherapy. Currently, gemcitabine is the agent used most commonly but demonstrates only a partial response. The transcription factor nuclear factor-kappaB (NF-κB), known to be involved in the inflammatory response, is constitutively activated in PDAC and further activated by gemcitabine. Our aim was to examine the effects of targeted NF-κB suppression on gemcitabine resistance using an in vivo tumor growth model. Methods To suppress the NF-κB pathway, the mutant IκBα super-repressor protein was stably expressed in PaCa-2 human PDAC cells. Athymic mice were injected subcutaneously with IκBα-super-repressor (SR) or vector-expressing PaCa-2 cells and randomized to receive phosphate-buffered saline (PBS) or 100 mg/kg gemcitabine(gem) for 4 weeks. Results The mean increase in tumor volume was 47 mm3 (89%) and 196 mm3 (326%) in gem/SR and gem/vector groups, respectively (P =.03). The PBS-treated groups demonstrated greater tumor growth, ∼340 mm3 (850%) increase, in both PBS/vector and PBS/SR groups. Intratumoral NF-κB activity was decreased in gem/SR compared with the gem/vector group (P =.04). Decreased Ki-67 positivity was noted in gem/SR (49%) versus gem/vector tumors (73%) (P =.04), with no difference in apoptosis (apoptag, P =.3) or angiogenesis (CD31+, P =.9). Conclusion Stable IκBα-SR expression in vivo potentiated the antitumor effects of gemcitabine, resulting in decreased tumor growth in association with decreased cell proliferation. Molecular suppression of the NF-κB pathway decreases successfully gemcitabine resistance in a relatively chemoresistant PDAC line. Thus, NF-κB-targeted agents may complement gemcitabine-based therapies and decrease chemoresistance in patients with PDAC.

AB - Background Pancreatic ductal adenocarcinoma (PDAC) is an almost uniformly fatal malignancy characterized by resistance to chemotherapy. Currently, gemcitabine is the agent used most commonly but demonstrates only a partial response. The transcription factor nuclear factor-kappaB (NF-κB), known to be involved in the inflammatory response, is constitutively activated in PDAC and further activated by gemcitabine. Our aim was to examine the effects of targeted NF-κB suppression on gemcitabine resistance using an in vivo tumor growth model. Methods To suppress the NF-κB pathway, the mutant IκBα super-repressor protein was stably expressed in PaCa-2 human PDAC cells. Athymic mice were injected subcutaneously with IκBα-super-repressor (SR) or vector-expressing PaCa-2 cells and randomized to receive phosphate-buffered saline (PBS) or 100 mg/kg gemcitabine(gem) for 4 weeks. Results The mean increase in tumor volume was 47 mm3 (89%) and 196 mm3 (326%) in gem/SR and gem/vector groups, respectively (P =.03). The PBS-treated groups demonstrated greater tumor growth, ∼340 mm3 (850%) increase, in both PBS/vector and PBS/SR groups. Intratumoral NF-κB activity was decreased in gem/SR compared with the gem/vector group (P =.04). Decreased Ki-67 positivity was noted in gem/SR (49%) versus gem/vector tumors (73%) (P =.04), with no difference in apoptosis (apoptag, P =.3) or angiogenesis (CD31+, P =.9). Conclusion Stable IκBα-SR expression in vivo potentiated the antitumor effects of gemcitabine, resulting in decreased tumor growth in association with decreased cell proliferation. Molecular suppression of the NF-κB pathway decreases successfully gemcitabine resistance in a relatively chemoresistant PDAC line. Thus, NF-κB-targeted agents may complement gemcitabine-based therapies and decrease chemoresistance in patients with PDAC.

UR - http://www.scopus.com/inward/record.url?scp=84940793350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940793350&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2015.04.043

DO - 10.1016/j.surg.2015.04.043

M3 - Article

C2 - 26209568

AN - SCOPUS:84940793350

VL - 158

SP - 881

EP - 889

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 4

ER -